Skip to content
Revision Rate of Direct-to-Implant Breast Reconstruction: Is it Truly a Single-Stage Reconstruction? A Single-Surgeon Experience.
Adler N, Carmon E, Houri P.
Aesthetic Plast Surg. 2022 Oct 28. doi: 10.1007/s00266-022-03136-7. Epub ahead of print.
Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B, Helms M, Besch L, Kalmbach N, Stegen S, Blohmer JU, Speiser D.
Arch Gynecol Obstet. 2022 Oct 28. doi: 10.1007/s00404-022-06819-3. Epub ahead of print.
Germline mutations in 5' to c.7914 of BRCA2 significantly increase risk of prostate cancer.
Ruan XH, Huang D, Lin XL, Fang ZJ, Ding Q, Wu YS, Na R.
Asian J Androl. 2022 Oct 28. doi: 10.4103/aja202277. Epub ahead of print.
Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
Coelho R, Tozzi A, Disler M, Lombardo F, Fedier A, López MN, Freuler F, Jacob F, Heinzelmann-Schwarz V.
Cell Death Dis. 2022 Oct 28;13(10):909. doi: 10.1038/s41419-022-05347-x.
Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer.
Evron E, Ben-David MA, Kaidar-Person O, Corn BW.
J Clin Oncol. 2022 Oct 28:JCO2201609. doi: 10.1200/JCO.22.01609. Epub ahead of print.
Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.
Negri S, De Ponti E, Sina FP, Sala E, Dell'Oro C, Roversi G, Lazzarin S, Delle Marchette M, Inzoli A, Toso C, Fumagalli S, Campanella M, Kotsopoulos J, Fruscio R.
Mol Genet Genomic Med. 2022 Oct 28:e2071. doi: 10.1002/mgg3.2071. Epub ahead of print.
Library adaptors with integrated reference controls improve the accuracy and reliability of nanopore sequencing.
Gunter HM, Youlten SE, Madala BS, Reis ALM, Stevanovski I, Wong T, Kummerfield SK, Deveson IW, Santini NS, Marcellin E, Mercer TR.
Nat Commun. 2022 Oct 28;13(1):6437. doi: 10.1038/s41467-022-34028-8.
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Shimon P; ESMO Guidelines Committee.
Ann Oncol. 2022 Oct 19:S0923-7534(22)04193-X. doi: 10.1016/j.annonc.2022.10.004. Epub ahead of print.
Age-Dependent Heterogeneity of Lymph Node Metastases and Survival Identified by Analysis of a National Breast Cancer Registry.
Behring M, Bajpai P, Afaq F, Elkholy A, Kim HG, Al Diffalha S, Shrestha S, Manne U.
J Pharm Pharmacol Res. 2022;6(3):147-157. doi: 10.26502/fjppr.060. Epub 2022 Sep 19.
Post navigation